Health Condition 1: I739- Peripheral vascular disease, unspecified
Conditions
Interventions
Intervention1: Credenceâ?¢ BRS Sirolimus Eluting BioResorbable Peripheral Scaffold System: Credenceâ?¢ BRS Sirolimus Eluting BioResorbable Peripheral Scaffold System
Control Intervention1: Nil: Nil
Sponsors
Meril Life Sciences Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Subject is >=18 years of age. 2. Subject has been informed of the nature of the study, and has provided written informed consent, approved by the appropriate Institutional Review Board (IRB) of the respective clinical site. 3. Subject is diagnosed as having symptomatic claudication (Rutherford-Becker Clinical Category 1-3). a. For subjects with bilateral lesions, the higher Rutherford-Becker clinical category limb will be considered the target b. If both limbs are of the same Rutherford Becker clinical category, the target extremity will be selected based on investigator discretion. 4. Subject agrees to undergo all protocol-required follow-up examinations and requirements at the investigational site. 5. Female subject of childbearing potential must have had a negative pregnancy test within 14 days before treatment; not be nursing at the time of the study procedure and agree at time of consent to use birth control during participation in this trial. 6. Subject has life expectancy > 12 months. 7. Subject is able to take clopidogrel or prasugrel (or ticlopidine, if the subject cannot take clopidogrel or prasugrel) and acetylsalicylic acid (aspirin). 8. Subject must agree not to participate in any other clinical investigation for a period of 5 years following the index procedure. This includes clinical trials of medications and invasive procedures. Questionnaire-based studies, or other studies that are non-invasive and do not require medication are allowed. Angiographic Inclusion Criteria: 1. Reference vessel diameter (RVD) 2.0-10.0 mm measured by an objective measurement such as online Quantitative Vessel Analysis (QVA). 2. Target lesion is >= 50% DS. 3. Target lesion length 4. Patent inflow artery free from significant lesion (>= 50% DS and 5. Patent popliteal artery free from significant lesion (>= 50% DS) with at least one patent distal outflow artery (anterior tibial, posterior tibial, or peroneal) that provides in-line circulation to the lower leg and foot, as confirmed by angiography.
Exclusion criteria
Exclusion criteria: 1. Acute or chronic renal dysfunction (creatinine > 2.5 mg/dl or >176μmol/L). 2. Severe liver impairment as defined by total bilirubin >= 3 mg/dl or two times increase over the normal level of serum glutamic oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT). 3. A platelet count 700,000 cells/mm3; a white blood cell count (WBC) 4. Known allergies to the following: aspirin, clopidogrel, prasugrel or ticlopidine, heparin, contrast agent (that cannot be adequately premedicated), or drugs similar to sirolimus (i.e. tacrolimus, everolimus, zotarolimus) or other macrolides. 5. Subject requires planned procedure that would necessitate the discontinuation of clopidogrel, prasugrel or ticlopidine. 6. Subject has had or will require treatment with drug eluting stent (DES) or drug coated balloon (DCB) within 6 months pre- or post-index procedure. 7. Subject is unable to walk. 8. Subject has undergone any non-iliac percutaneous intervention, e.g. coronary, carotid, 9. Subject has received, or is on the waiting list for, an organ transplant. 10. Subject is on chronic haemodialysis. 11. Subject has uncontrolled diabetes mellitus (DM) (HbA1c >= 7.0%). 12. Subject has had a myocardial infarction (MI) within the previous 30 days of the planned index procedure. 13. Subject has unstable angina defined as rest angina with ECG changes. 14. Subject has a groin infection, or an acute systemic infection that has not been treated successfully or is currently under treatment. 15. Subject has acute thrombophlebitis or deep vein thrombosis in either extremity. 16. Subject has other medical illnesses (e.g., cancer or congestive heart failure) that may cause the subject to be non-compliant with protocol requirements, confound the data interpretation or is associated with limited life-expectancy, i.e., less than 12 months. 17. Subject is currently participating in an investigational drug, biologic, or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints. (Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.) 18. Subject is unable to understand or unwilling to cooperate with study procedures. 19. Subject requires general anesthesia for the procedure. 20. Subject has ischemic or neuropathic ulcers on either foot. 21. Subject has prior minor or major amputation of either lower extremity. 22. Subject is part of a vulnerable population who, in the judgment of the investigator, is unable to give informed consent for reasons of incapacity, immaturity, adverse personal circumstances or lack of autonomy. 23.Subject has had a stroke within the previous 30 days of the planned index procedure and/or has deficits for from a prior stroke that limits the subjects ability to walk. Angiographic Exclusion Criteria: 1. Contralateral lesion distal to the location of inguinal ligament that requires treatment within 30 days before or after the procedure. (Contralateral iliac artery lesions may be treated during the pr
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| long-term patency outcomes include drug-eluting stents (DES) and drug-coated balloons (DCB) that deliver antirestenotic agents to the vessel wall and self-expanding covered stents or stent-grafts that prevent neointimal in growth at the site of treatmentTimepoint: 1 Month,6 Months,12 Months, 2 years,3 years,4 years and 5 years | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Technical success of the stenting procedure.Technical Success is defined as delivery and deployment of the assigned study stent to the target lesion to achieve residual angiographic stenosis no greater than 30% assessed visually 2. Procedural success of the stenting procedure. Procedural Success is defined as technical success with no MAEs noted within 24 hours of the index procedure 3. Clinically-driven TLR Rate.Timepoint: 1 Month,6 Months,12 Months, 2 years,3 years,4 years and 5 years | — |
Countries
India
Contacts
Public ContactDr Ashok Thakkar
Meril Life Sciences Pvt LTd
Outcome results
None listed